pharmaphorum

OCTOBER 24, 2024

Denmark's Lundbeck has said that efforts to build its R&D portfolio are on track to deliver four new molecular entities (NMEs) in phase 3 trials in 2026, including an epilepsy drug from its recently announced $2.6 billion takeover of Longboard Pharma.

Pharma 105

Pharma 105

Fierce Pharma

SEPTEMBER 5, 2023

The case was filed Friday in New Jersey federal court, three days after the CMS revealed that Novartis’ heart failure treatment Entresto was among 10 drugs subject to price negotiations in 2026.

Biopharma 306

Biopharma Government 306

European Pharmaceutical Review

SEPTEMBER 12, 2023

Over 50 percent of respondents answered that machine learning for optimisation of manufacturing processes will be the technology that will be used routinely in the pharmaceutical industry by 2026. The post AI to revolutionise drug development by 2026 appeared first on European Pharmaceutical Review.

Food and Drug Administration 105

Food and Drug Administration Manufacturing Pharmaceutical FDA 105

Fierce Pharma

MARCH 7, 2024

By Eisai’s 2026 fiscal year—which ends in March 2027—the company figures its Alzheimer's disease drug Leqembi can bring home 290 billion Japanese yen (nearly $2 billion) in global revenues. Come fiscal year 2032, those sales could potentially swell to a whopping 1.3 trillion yen ($8.8 billion).

Sales 275

Sales 275

Fierce Pharma

SEPTEMBER 3, 2024

28, 2026. Reddy’s formulations production plant, China’s National Medical Products Administration has suspended the import, sale and use of the Indian drugmaker’s atomoxetine hydrochloride capsules for ADHD. In addition, Dr. Reddy’s is prohibited from taking part in China’s drug procurement scheme through Feb.

Manufacturing 264

Manufacturing Sales Medical 264

Fierce Pharma

OCTOBER 9, 2023

billion) for exclusive rights to distribute the shingles shot in China from 2024 through 2026. GSK has forged a partnership with vaccine powerhouse Chongqing | GSK has forged a partnership with vaccine powerhouse Chongqing Zhifei Biological Products to distribute Shingrix in China. Zhifei will pay £2.5 billion ($3.05

Distribution 290

Distribution 290

Fierce Pharma

SEPTEMBER 12, 2023

28, 2026. The deal clears “all pending claims” and tees up a potential Dasynoc launch on Sept. 1, 2024, or potentially earlier under certain circumstances. The Sprycel patents in question aren’t due to expire until Sept.

FDA 290

FDA Pharma 290

Fierce Pharma

OCTOBER 7, 2024

GSK’s ViiV healthcare unit is countering rival HIV drugmaker Gilead’s recent global access moves with its own pledge to make at least 2 million doses of its long-acting pre-exposure prophylaxis (Pr | The long-acting HIV PrEP maker pledged to make at least 2 million more doses available for low-and middle-income countries in 2025 and 2026.

Healthcare 246

Healthcare Healthcare 246

Fierce Pharma

OCTOBER 27, 2023

In August, Imbruvica was one of the 10 drugs identified by the CMS that will be subject to price negotiations in 2026. . | Sales of AbbVie and Johnson & Johnson’s leukemia blockbuster Imbruvica are taking a hit from BeiGene’s Brukinsa. But what about the impact of the Inflation Reduction Act?

Sales 278

Sales 278

Fierce Pharma

DECEMBER 14, 2023

Ahead of 2026’s Medicare drug price negotiations, the White House is getting ready to crack down on companies who’ve raised the costs of their medications faster than the rate of inflation.

Medical 234

Medical 234

Fierce Pharma

NOVEMBER 12, 2024

The cash will be used to grow the company’s research and production footprint in the States by the end of 2026, generating more than 1,000 new jobs along the way. . | AstraZeneca on Tuesday revealed that it’s adding $2 billion more to its current outlay in the U.S., representing a total capital investment of $3.5

Manufacturing 189

Manufacturing 189

Fierce Pharma

JUNE 10, 2024

Colorado’s Prescription Drug Affordability Review Board (PDAB) isn’t waiting for the Inflation Reduction Act (IRA) to lower prices on certain drugs starting in 2026. After the review board unanimously agreed that Stelara is "unaffordable," the drug could be subject to an upper payment limit in the state.

Prescription 189

Prescription Marketing 189

Fierce Pharma

NOVEMBER 4, 2024

The deal is expected to extend Nektar's cash runway into 2026 and help the company hone its development of novel immunology drugs.

Manufacturing 189

Manufacturing Sales 189

Pharmaceutical Technology

NOVEMBER 19, 2024

Regenxbio’s plans toward a BLA filing in 2026 after positive data from the Phase I/II AFINITY DUCHENNE trial.

52

52

MedCity News

AUGUST 15, 2024

The first 10 drugs selected for Medicare price negotiations now have new prices set to take effect in 2026. Industry observers note that most of these drugs are older products facing generic competition soon, so greater industry impact will come as the program expands to more drugs in years to come.

Competition 130

Competition Biopharma Pharma 130

MedCity News

OCTOBER 3, 2024

The firm predicts in-progress lab construction will decline to pre-pandemic levels by 2026. Laboratory construction has waned in the past two years due to the end of the pandemic and an economic slowdown, according to a new report from CBRE.

Biopharma 126

Biopharma Pharma 126

pharmaphorum

MAY 3, 2024

AI-powered home healthcare model from Cera could save NHS and UK £1bn in 2026 if adopted nationwide, says new study

Healthcare 108

Healthcare Healthcare 108

World of DTC Marketing

MAY 9, 2022

Online Ad Stats : Social media advertising budgets are expected to grow 11.76% annually by 2026. billion by 2026 , is still a new frontier of the digital world, an all but lawless Wild West where a few major industry players have seized territory for their gain. Online ad fraud is costing pharma millions.

Pharma 208

Pharma Media Marketing Sales 208

MedCity News

MAY 15, 2023

The royalty deal extends uniQure’s cash runway into 2026. By selling partial royalties to approved hemophilia gene therapy Hemgenix, uniQure gains immediate cash to support its pipeline, including a Huntington’s disease gene therapy already in the clinic.

Biopharma 116

Biopharma Pharma 116

PharmaVoice

OCTOBER 23, 2024

As Sanofi prepares to halt production on its dengue vaccine in 2026, locally acquired infections in the U.S. are raising the alarm.

98

98

Pharmaceutical Commerce

AUGUST 16, 2024

By 2026, the first 10 drugs for individuals with Part D coverage—whose medications are mainly used to treat cancer, diabetes, and heart disease—will see discounts off of list prices ranging from 38-79%.

Medical 98

Medical 98

pharmaphorum

NOVEMBER 12, 2024

AstraZeneca plans to invest a whopping $3.5

Biopharma 98

Biopharma Sales Manufacturing Pharma 98

Scott Burrows

JULY 5, 2022

By 2026, industry experts expect EV sales to quadruple from 2020,… As an insurance and financial speaker with strong ties to the industry, I have not seen such interesting—and positive—developments in years. For example, according to Statista the sales of electric vehicles are on the verge of explosion.

Insurance 98

Insurance Sales 98

PharmExec

AUGUST 29, 2023

Lawsuit comes amid announcement of the first 10 drugs eligible for negotiated prices in 2026.

75

75

World of DTC Marketing

FEBRUARY 22, 2021

billion by 2026. One of the most common complaints people have is “lack of energy” Consumers have turned to energy drinks which was valued at $53.01 billion in 2018, and is expected to grow at a CAGR of 7.20% to reach $86.01

Pharma 181

Pharma Doctors Side effects Prescription 181

Pharmaceutical Technology

JULY 20, 2023

The centre is planned for completion in 2026, along with plans to build a $400m biologics manufacturing plant.

Manufacturing 74

Manufacturing 74

European Pharmaceutical Review

JULY 10, 2023

billion in 2026. Given their short shelf-life, there is a need for methods that generate more rapid results for emerging advanced therapy medicinal products (ATMPs) such as cell and gene therapies. Currently, there are more than 2,000 active clinical trials for cell and gene therapies, 1 with the market expected to grow from $8.6

Pharmaceutical products 98

Pharmaceutical products Manufacturing Medicine Pharmaceutical 98

Clear Pivot

SEPTEMBER 22, 2022

billion by 2026 , so take the steps to create a successful medtech marketing strategy now as the industry is still growing. However, while your product is the backbone of your success, you must also successfully market it to buyers. Revenue from the medical technology industry is projected to reach $644.20

Marketing 76

Marketing Competition Medical Healthcare 76

Pharmacy Times

AUGUST 15, 2024

The new prices are expected to go into effect for patients with Medicare Part D on January 1, 2026.

Patients 59

Patients 59

Pharmaceutical Technology

NOVEMBER 8, 2023

The company’s cash reduction measures are expected to extend its cash runway into 2026.

64

64

PharmaVoice

AUGUST 16, 2024

The final negotiations slash drug prices between 38% and 79% for Medicare’s 2026 calendar year.

59

59

World of DTC Marketing

OCTOBER 27, 2020

By 2026, national health expenditures will reach $5.7 health care spending reached $3.7 trillion in 2018 – about $11,200 per person. Health care spending is approaching nearly one-fifth of the U.S. gross domestic product. That’s $1 in every $5 in the national economy. trillion – over $16,000 per capita.

Healthcare 230

Healthcare Healthcare Insurance Retail 230

European Pharmaceutical Review

JUNE 28, 2022

billion by 2026, achieving a compound annual growth rate (CAGR) of 13.2 percent CAGR between 2022 and 2026. According to recent market research , the global market for biopharmaceutical bioseparation systems, estimated to value $13 billion in 2022, is projected to grow to $19.6

Marketing 111

Marketing Government Healthcare Healthcare 111

Pharmaceutical Technology

SEPTEMBER 23, 2022

It will expire on 24 November 2026, and the paediatric exclusivity lasts until 24 May 2027. Additionally, Merck has signed patent litigation settlement deals with various generic firms, permitting them to offer generic versions of Januvia and Janumet to the US market in May 2026, or before under specific conditions.

Food and Drug Administration 69

Food and Drug Administration FDA Food Marketing 69

European Pharmaceutical Review

MAY 27, 2024

Eli Lilly anticipates that medicine production at the Lebanon site will begin near the end of 2026. A learning and training centre will be part of the larger Limitless Exploration Advanced Pace (LEAP) Research and Innovation District industrial development, Eli Lilly confirmed.

Manufacturing 105

Manufacturing Medicine Engineering Pharmaceutical 105

European Pharmaceutical Review

SEPTEMBER 12, 2024

Production is expected to begin in 2026. Lilly noted that these include engineers, scientists, quality assurance professionals and operations personnel, totalling 450 employees at the facility. Kinsale site Additionally, expansion of Lilly’ Kinsale facility will be funded by an $800 million investment.

Manufacturing 105

Manufacturing Medicine Engineering Pharmaceutical 105

PharmaVoice

NOVEMBER 5, 2024

Rallybio is headed into a mid-stage trial with enough cash through 2026, but the cyclical market has made the journey difficult.

Marketing 52

Marketing 52